Kadcyla (Trastuzumab Emtansine)

Trastuzumab emtansine combines a monoclonal antibody that binds HER2 receptors with the cytotoxic agent DM1. After binding to HER2‑expressing cancer cells, the complex is internalized, releasing DM1, which disrupts microtubules, causing cell‑cycle arrest and apoptosis while the antibody blocks HER2 signaling.

The prescribed dose of Kadcyla is determined by the treating oncologist based on the patient’s clinical condition, body weight, and treatment protocol. Dosing regimens are individualized and should follow the prescribing information provided by the healthcare professional.

Kadcyla’s safety in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential risks to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period afterward.

To order Kadcyla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Kadcyla differs from other HER2‑targeted agents such as trastuzumab alone because it delivers a cytotoxic payload (DM1) directly to HER2‑expressing cells, providing both antibody‑mediated inhibition and chemotherapy. This dual mechanism can offer benefit in patients who have progressed on standard HER2 therapies.

Kadcyla must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Once prepared for infusion, the solution should be used within the time frame specified in the product labeling.

Kadcyla is given as an intravenous infusion. The drug is supplied as a sterile powder that is reconstituted and diluted according to the prescribing information, then infused over a period of typically 30 to 90 minutes under medical supervision.

Serious risks include interstitial lung disease or pneumonitis, cardiac dysfunction (reduced left ventricular ejection fraction), severe hepatic toxicity, significant bleeding, and infusion‑related reactions. Patients should be monitored closely for symptoms of these conditions throughout treatment.

Kadcyla is contraindicated in patients with known hypersensitivity to trastuzumab, emtansine, or any component of the formulation. It should also be avoided in individuals with uncontrolled cardiac disease, active severe infections, or those who are pregnant or breastfeeding.